Miller Austinn C, Watson Abigail E, Inglese Marc J
University of Central Florida/HCA Healthcare Consortium, Tallahassee, FL, USA.
Dermatology Associates of Tallahassee, Tallahassee, FL, USA.
Skin Therapy Lett. 2025 Mar;30(2):1-4.
Seborrheic dermatitis (SD) is a chronic inflammatory skin disorder most commonly affecting areas rich in sebaceous glands, such as the scalp, face, axilla, and groin. Several factors can precipitate SD development, such as colonization of Malassezia, sebocyte activity, impaired immunity, and environmental influences. Topical antifungals, corticosteroids, and calcineurin inhibitors are the current mainstay treatment of SD. Recent clinical trials have validated the efficacy of non-steroidal roflumilast 0.3% foam for the treatment of SD. In this review, we analyze the safety and efficacy profile of roflumilast 0.3% foam.
脂溢性皮炎(SD)是一种慢性炎症性皮肤病,最常累及皮脂腺丰富的区域,如头皮、面部、腋窝和腹股沟。多种因素可促使脂溢性皮炎的发生,如马拉色菌定植、皮脂腺细胞活性、免疫功能受损及环境影响。局部用抗真菌药、皮质类固醇和钙调神经磷酸酶抑制剂是目前脂溢性皮炎的主要治疗方法。最近的临床试验证实了0.3%的非甾体类罗氟司特泡沫剂治疗脂溢性皮炎的有效性。在本综述中,我们分析了0.3%罗氟司特泡沫剂的安全性和疗效。